DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Clevudine
Clevudine
Inclusion and Exclusion Criteria for Each Key Question
Tanibirumab (CUI C3490677) Add to Cart
Clevudine Induced Mitochondrial Myopathy
DNA/RNA Synthesis
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Appendices: V Ervolgonderzoek Medicatieveiligheid
Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
(12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
Malaysian Statistics on Medicines 2007
Application Number
Comparison of Clinical Practice Guidelines for the Management of Chronic Hepatitis B: When to Start, When to Change, and When to Stop
Response of Imiquimod Based Toll Like Receptor 7 Ligand in Hbv-Positive Human Hepatocelluar Carcino
Stembook 2018.Pdf
Final1-Aritmo-Final-Report-V2-0Final.Pdf
Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
Repurposing of FDA Approved Drugs
Review 0103 - 5053 $6.00+0.00
Update on Chronic Hepatitis B
Top View
National Horizon Scanning Centre Clevudine (Levovir) for Hepatitis B August 2008
In HBV-Infected Subjects D
Recent Advances in Hepatitis B Treatment
1 Identification of Potent Drugs and Antiviral Agents for the Treatment Of
Clevudine Myopathy in Patients with Chronic Hepatitis Bq
Study Protocol
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Medical Product Quality Report – COVID-19 Issues
Antiviral Therapy for Chronic Hepatitis B and C
UNDP-Using Competition Law to Promote Access to Health
Customs Tariff - Schedule Xxi - 1
Learn About Chronic Hepatitis B and How Vemlidy May Help. Download
Australian Statistics on Medicines 2009
Embase 1988 to 2014 Week 36, Ovid MEDLINE(R) In-Process
Optimal Management of Clevudine Resistant Chronic Hepatitis B; a Multicenter Cohort Study
(12) Patent Application Publication (10) Pub. No.: US 2010/0226943 A1 Brennan Et Al
Harmonized Tariff Schedule of the United States (2006) (Rev
Options of Antiviral Treatment
WO 2016/169573 Al 27 October 2016 (27.10.2016) P O P C T
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(T)Ide Analogue Therapy
Potential Anti-SARS-Cov-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: a Comprehensive Review
Pharmaceutical Appendix to the Tariff Schedule 2
COVID User's Guide (Updated: 14/12/2020)
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Diplomarbeit
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
29Th International Conference on Antiviral Research (ICAR) 2 International Conference on DAILY Antiviral Research (ICAR) SCHEDULE
REVIEW ARTICLE Overview of Anti-Hepatitis B Virus Agents INTRODUCTION
Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections †
Efficacy of Peginterferon Alpha-2B in Chronic Hepatitis Delta: Relevance of Quantitative RT-PCR for Follow-Up
Australian Statistics on Medicines 2010
Supplemental Table 1: Inclusion and Exclusion Criteria
ARPEC Protocol for Drug Utilization Study
Surveillance of Antimicrobial Consumption in Europe 2012 Surveillance of Antimicrobial Consumption in Europe 2012
A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection
Modified Fluorinated Nucleoside Analogues Modifizierte Fluorinierte Nukleosidanaloga Analogues De Nucléosides Fluorés Modifiés